As regulation surrounding psychedelics develops across the globe, Numinus Wellness has created a toxicity and potency screening test that will facilitate safety and efficacy testing of the substances.
Focusing on psychedelics-based mental healthcare, Numinus has developed proprietary psychedelic tests that can screen mushroom compounds for toxicity and potency.
This analytical testing will be available as part of Numinus’ service offerings for third-party clients and used for evidence-based conversations about psychedelic substances with regulators.
Sharan Sidhu, science officer and general manager, commented: “The testing we’ve developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry.
“Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products.”
Amongst the matrices for which methodologies are being developed are psilocybe mushroom fruiting bodies, extracts, and derivatives and, coupled with required testing such as contaminants and residues, the lab has validated methods for active constituents.
The psilocybe mushrooms constituent screen includes psilocybin, psilocin, baeocystin, norbaeocystin and tryptophan, norpsilocin and aeruginascin, which represent the most well-defined alkaloids for psilocybe species.
The psychedelic mushroom toxicity screen includes nephrotoxic and hepatotoxic compounds, and Numinus says that, although the platform has been developed for industry, the screen can quickly identify toxins from several varied species. The screen is being offered to healthcare providers to identify toxins in poison control responses, demonstrating the value of this research beyond the psychedelic industry.
Toxicity scans are completed using the Orbitrap, a state-of-the-art, high-resolution mass spectrometry instrument.
Payton Nyquvest, CEO and Founder, Numinus, added: “These in-house validated methods are another example of success in analytical development at Numimus, showing our commitment to strengthen regulatory confidence in these products.
“We continue to push the boundaries as we establish our role as The Center of Excellence for Psychedelic Research and Development, with the furtherment of the industry at the heart of our advancements.”
So far, the Numinus research team has characterised over 260 compounds, many of them characterised for the first time in psychedelic mushrooms, and continues to make novel discoveries in the research and development of psilocybin. The company has said that it is continuing to build testing capabilities for ketamine, LSD, mescaline, DMT and MDMA.
[activecampaign form=52]
